German oncology databases: options and assessment for real-world evidence

Verfasst von Winnie Wu

Which German oncology data sources can be used for real-world evidence (RWE) studies, and which one is right for your research question? The GIPAM / OncoCase team has published a whitepaper that gives an overview of the oncology data sources available in Germany and assesses their potential for RWE research.

Key takeaways

  • There is no single ideal data source for oncology RWE in Germany.

  • The study objectives determine whether claims data or oncology electronic health record (EHR) data should be used.

  • Depending on the research question, a chart review or a prospective observational study may be the better option.

The whitepaper is a practical guide for researchers, pharmaceutical companies and HTA teams planning oncology RWE studies in Germany.

Download the whitepaper: https://www.oncocase.de/s/Whitepaper-GIPAM-GER-Oncology-Database-5Sep2025.pdf

Winnie Wu
Weiter

Lung cancer in Germany: incidence and survival trends from ZfKD registry data (2020-2023)